Literature DB >> 15907292

128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands.

Francesco Muntoni1, Kate Bushby, Gertjan van Ommen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15907292     DOI： 10.1016/j.nmd.2005.02.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  6 in total

Review 1.  Therapeutics in duchenne muscular dystrophy.

Authors:  Jonathan B Strober
Journal:  NeuroRx       Date:  2006-04

Review 2.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 3.  Optimizing exon skipping therapies for DMD.

Authors:  T Yokota; W Duddy; T Partridge
Journal:  Acta Myol       Date:  2007-12

Review 4.  Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications.

Authors:  Akinori Nakamura; Shin'ichi Takeda
Journal:  J Biomed Biotechnol       Date:  2011-01-05

5.  Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.

Authors:  Keng Boon Wee; Zacharias Aloysius Dwi Pramono; Jian Li Wang; Karl F MacDorman; Poh San Lai; Woon Chee Yee
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

Review 6.  Antisense therapy in neurology.

Authors:  Joshua J A Lee; Toshifumi Yokota
Journal:  J Pers Med       Date:  2013-08-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.